A new study by Sylvester Comprehensive Cancer Center researchers shows that daily MRI imaging paired with radiation can monitor tumor changes in real-time. The technology has the potential to signal early warning signs of tumor growth, allowing for faster and more targeted treatment adaptations.
A new study found that Hispanic non-small cell lung cancer patients in South Florida tend to be diagnosed at earlier stages than White patients, with a lower likelihood of advanced-stage diagnoses. This disparity disappears when examining ethnic subpopulations within the Hispanic population.
A new study suggests a mouthwash-based test can help physicians predict disease recurrence in head and neck cancer patients by detecting biomarkers in saliva. Elevated levels of CD44 and total protein were associated with increased recurrence risk, highlighting the potential for early detection and reducing morbidity and mortality.
A study identifies a 10-gene biomarker that can predict whether stage II or III colon cancer patients will benefit from adjuvant chemotherapy. The gene signature also has the potential to predict which patients may respond to immunotherapy.
A study by Sylvester Comprehensive Cancer Center found that durvalumab, a targeted immunotherapy for lung cancer, exceeded official cost-effectiveness thresholds in four countries: the US, Brazil, Singapore, and Spain. The drug's high cost-effectiveness ratio was due to its extended lifespan and quality-of-life benefits.
A study presented at ASCO highlights biases reported by female cancer physicians, including racial and ethnic discrimination. The researchers emphasize the importance of representation and diversity in overcoming these issues.
Quadruple therapies offer deeper responses and longer clinical benefits for patients with newly diagnosed multiple myeloma. The addition of an immunotherapy agent to the backbone of small molecule drugs may improve overall survival and reduce the need for bone marrow transplants.
Researchers at Sylvester Comprehensive Cancer Center have developed a new treatment approach that enables more patients with high-risk blood cancers to receive stem cell transplants from unrelated, partially matched donors. The study found an overall survival rate of 79% and impressive metrics in high-risk patients.
The FDA committee voted unanimously to approve minimal residual disease (MRD) as a new clinical endpoint for evaluating proposed drugs to treat multiple myeloma. A meta-analysis led by C. Ola Landgren shows a strong correlation between MRD and clinical outcomes in newly diagnosed and relapsed patients.
A study published in Blood Neoplasia reveals that older adults with acute myeloid leukemia can benefit from standard treatment, with roughly a quarter experiencing durable prolonged survival. The conventional treatment of venetoclax combined with a hypomethylating agent (HMA) is safe and effective for those over 80 years old.
A multidisciplinary team of Caribbean authors has developed innovative solutions to safeguard cancer patients from climate-driven disasters. The research highlights the urgent need for climate-resilient healthcare infrastructure in developing regions.
Researchers at Sylvester Comprehensive Cancer Center have developed a nanoparticle that can penetrate the blood-brain barrier, potentially targeting both primary breast cancer tumors and brain metastases in one treatment. The method shows early promise in preclinical models, where it shrinks breast and brain tumors.
The newly updated guidelines provide clinicians with the latest recommendations for staging and management of neuroendocrine tumors. The guidelines highlight recent changes for treating these tumors, including emerging molecular imaging techniques known as theranostics.
A global plan to combat the projected surge in prostate cancer cases worldwide by 2040 highlights the need for increased screening among high-risk populations. The report emphasizes the importance of targeted community outreach, including mobile vans, to provide earlier diagnoses and improve treatment outcomes.
A new study from the University of Miami Miller School of Medicine shows that community-based screening and treatment for Helicobacter pylori bacterium infection can identify and eliminate high-risk individuals. The approach aims to prevent gastric cancer in vulnerable populations, including Blacks, Asians, and Latinos.
The Sylvester Comprehensive Cancer Center researchers will investigate the genetics behind endometrial cancer in Black women and its awareness among different populations. They aim to identify high-risk women, understand hereditary mutations, and raise physician awareness.
The Lancet Public Health paper emphasizes the need for a paradigm shift in bereavement care, with researchers advocating for transitional care models that integrate hospital and community-based support. The proposed model aims to bolster community capacity to support grievers and prioritize bereavement as a vital part of ethical health...
Researchers identified a next-generation BTK degrader that can destroy cellular targets and shrink tumors in drug-resistant CLL patients. The compound, NX-2127, showed promising results in laboratory studies and a phase 1 clinical trial.
Researchers at the University of Miami Miller School of Medicine have discovered that glioblastoma cells can mimic healthy neurons, evading drugs and immune systems. They identified key enzymes and protein modifications, including BRAF, which shows promise as a potential therapy target.
A new computational model, IRMMa, predicts personalized prognosis for newly diagnosed multiple myeloma patients based on tumor genomics and treatments. The model improves on previous prognostic tools by taking into account individualized risk and distinct subtypes of the disease.
A new study from Sylvester Comprehensive Cancer Center suggests that prophylactic treatment can significantly reduce the rate of cytokine release syndrome (CRS) in multiple myeloma patients. This approach could eliminate hospital stays and broaden access to immunotherapy treatments for more cancer patients.
A new study led by Dr. Mikkael Sekeres found that patients with a common form of acute myeloid leukemia reported better quality of life when treated with quizartinib, which targets the FLT3-ITD mutation. The study also showed minimal side effects and improved survival rates compared to those who didn't receive the drug.
A study found country of birth to be a significant risk factor for gastric intestinal metaplasia, a precursor to stomach cancer. Countries in Latin America and the Caribbean showed varying rates of risk.
A multicenter study identifies genetic and immune-related changes that impact treatment responses in newly diagnosed multiple myeloma patients. The researchers found a complex interplay between tumor genomic features and immune microenvironment changes drives stronger treatment responses and prolonged progression-free survival.
The study highlights the significant role petrochemicals play in cancer risks through every stage of processing, from extraction to disposal. Communities like East Palestine, Ohio, face increased cancer risks due to air pollution, while climate change worsens healthcare disruptions for patients with cancer.
Researchers will study the impact of exercise, intermittent fasting, and their combination on fatigue, biomarkers of inflammation, and quality of life in women with advanced breast cancer. The trial aims to improve treatment tolerability and possibly life duration for these patients.
A recent study by Sylvester Cancer researchers used machine learning tools to predict tumor growth patterns in glioblastoma patients. The model achieved an overall accuracy of 86% in predicting three outcome classes, with 93% accuracy when predicting between no progression and any kind of progression.
A panel discussion at ASTRO 2023 sheds light on physician burnout, highlighting the prevalence of the issue in radiation oncology. Expert strategies for achieving work-life balance are presented as crucial to preventing burnout among practicing physicians.
Researchers developed a scoring system analyzing income, education, geographical location, access to care, and other factors to identify patients at increased risk of poor outcomes. The study found significant socioeconomic disadvantage associated with a 21% decrease in textbook outcomes and a 32% decrease in overall survival.
A study by researchers at the University of Miami Miller School of Medicine found that thoracic surgeons who treat lung cancer are helping to reduce patients' risk of opioid dependence. The ERATS protocol, which includes intercostal nerve blocks and safe pain relievers, enables earlier hospital discharge with nearly opioid-free recovery.
A study at the University of Miami Miller School of Medicine found that robot-assisted surgeries and improved pain-management initiatives led to earlier discharges for many patients. However, lower-income patients were less likely to be discharged on day one due to socioeconomic disparities.
Researchers found that patients' immune systems play a vital role in determining the duration of remission from multiple myeloma. Sustained minimal residual disease (MRD) negativity is associated with prolonged survival, with patients achieving MRD negativity for at least two years remaining free from multiple myeloma 10 years later.
The National Institute of General Medical Sciences has awarded a five-year grant to Sylvester Comprehensive Cancer Center researchers to better define the role of XPO1 in cancer. XPO1 is a nuclear export protein shown to play a role in many cancer types, including solid tumors and blood cancers.
A new analysis of liver cancer identified racial and ethnic differences in cause, as well as emerging trends for this highly fatal disease. The study found that liver cancer disproportionately affects people of low socioeconomic status, immigrants, veterans, and incarcerated populations.
Researchers at the University of Miami Miller School of Medicine identified distinct genomic events responsible for resistance to anti-BCMA and anti-GPRC5D immunotherapies in multiple myeloma. Mutations in the extracellular domain of BCMA impede T-cell binding without affecting protein expression or downstream signaling.
Researchers at Sylvester Comprehensive Cancer Center will investigate signaling mechanisms between myeloid-derived suppressor cells and pro-inflammatory cancer-associated fibroblasts in pancreatic cancer. The goal is to develop a nanoengineered immunotherapy that selectively disrupts these interactions to target treatment resistance.
Researchers at Sylvester Comprehensive Cancer Center are working on a new urine test to detect prostate cancer, reducing the need for invasive biopsies. They will use exosomes, small extracellular vesicles, as a promising new biomarker and collaborate with Exosome Diagnostics.
A new study highlights the difficulty in diagnosing blood disorders like myelodysplastic syndromes/neoplasms (MDS), which can lead to treatment mistakes. The researchers found that expert pathologists disagreed with local pathologists' diagnoses in about 20% of cases, leading to wrong initial treatments for patients.
Researchers advocate for NCI-designated cancer centers to bolster emergency preparedness and protect vulnerable patients from climate-driven disasters. Despite experience dealing with climate hazards, gaps in emergency preparedness were identified, including inadequate information for cancer patients.
A $7 million PCORI-funded study will examine the effectiveness of supervised and unsupervised exercise-and-diet interventions in pairs of older cancer patients and their caregivers. The five-year study aims to improve mental and physical functioning as well as physical activity and diet.
Sylvester Comprehensive Cancer Center researchers developed a first-of-its-kind orally administered drug Platin-L to disrupt prostate cancer cells' metabolism and deliver cisplatin directly into treatment-resistant cancer cells. The study showed that Platin-L is safe and effective in shrinking treatment-resistant cancers.
Researchers have identified a well-concealed genetic variation in the FGF14 gene causing late-onset cerebellar ataxia, a brain disorder affecting coordinated movement. The study's findings could lead to new diagnostic tools and treatments for patients suffering from this condition.
Inherited mutations in the MINAR2 gene cause deafness in four families, with progressive hearing loss in some affected individuals and mice. The study suggests these cases may be suitable for intervention with genetic therapies.
A national policy change facilitating broader sharing of donor livers through 'acuity circles' has resulted in procurement delays, averaging two to four hours. This added complexity affects organ procurement organizations and can emotionally tax families waiting for the organ.
Researchers have developed RNA molecules that selectively target human pancreatic beta cells, allowing for the delivery of therapies directly to these cells. This breakthrough enables the study of diabetes progression and provides new opportunities for precision treatments.
A study by University of Miami researchers has identified a gene mutation associated with preeclampsia, a disease that causes high blood pressure and organ damage in mothers and babies. The team tested a possible treatment involving vitamin C and found it alleviated symptoms in models, but its effectiveness is unclear.
A University of Miami researcher has discovered a polymer chain nanoparticle that can deliver antiretroviral drugs to the brain, reducing HIV/AIDS viral reservoirs. The breakthrough could improve the treatment of brain cancers and other diseases, particularly in HIV-positive individuals with neurological problems.
A large retrospective cohort analysis of 74,754 patients found that flu vaccination significantly reduces the risk of stroke, sepsis, and DVT in patients with COVID-19. Patients who received the flu shot were less likely to visit the emergency department and be admitted to ICU.
A study analyzed over 1,000 medical records from two US hospitals to examine potential disparities in resource allocation under crisis standards of care. The researchers found no evidence of bias against patients based on race or ethnicity.
Researchers developed a risk score to prioritize liver cancer patients for transplantation, accounting for both cancer-related and non-cancer-related factors. The LiTES-HCC score predicts post-transplant survival for hepatocellular carcinoma patients, leading to more efficient allocation of livers.